Adding thymosin beta-4 to antibiotic treatment for bacterial corneal infections in mice reduced harmful neutrophil infiltration and regulated the immune response without compromising bacterial killing.
Significant PMN reductionAdjunctive Tβ4 treatment reduced neutrophil infiltration into infected corneas while maintaining regulated immune function
What the researchers found
Adding thymosin beta-4 (Tβ4) to ciprofloxacin antibiotic treatment significantly improved outcomes in bacterial eye infections in mice. The combination reduced the number of neutrophils (PMNs) infiltrating infected corneas and downregulated pro-inflammatory markers on those cells. Tβ4 also promoted well-regulated production of reactive oxygen species (ROS) and neutrophil extracellular traps (NETs), with limited neutrophil death (apoptosis).
The study confirmed both in vivo and in vitro that Tβ4 modulates how neutrophils respond to infection — not by suppressing immunity, but by regulating it. An additional finding was that neutrophil elastase (NE) was unnecessary for NET formation (NETosis), challenging previous assumptions about how NETs are generated.
Why it matters
Bacterial keratitis (corneal infection) can cause vision loss, and while antibiotics kill the bacteria, the inflammatory damage from the immune response itself often causes much of the tissue destruction. Thymosin beta-4 addresses this dual problem — it works synergistically with antibiotics to fight infection while simultaneously preventing excessive immune-mediated tissue damage. This two-pronged approach could preserve more corneal tissue and improve visual outcomes.
The numbers in context
P. aeruginosa infection model · C57BL/6 mice · Significant reduction in PMN infiltration with Tβ4 + ciprofloxacin · Downregulated proinflammatory markers · Well-regulated ROS and NET production · Confirmed in vivo and in vitro
How the study worked
Researchers infected C57BL/6 mouse corneas with Pseudomonas aeruginosa bacteria and treated them with ciprofloxacin alone or ciprofloxacin plus Tβ4. Flow cytometry was used to profile infiltrating neutrophils. ROS production, NET formation, and neutrophil apoptosis were measured. In vitro experiments using peritoneal-derived neutrophils were conducted to verify and extend the in vivo results.
Who was studied
Female C57BL/6J mice with P. aeruginosa-induced corneal infection, plus peritoneal-derived neutrophils for in vitro studies
What this study cannot tell us
This is a mouse study and results may not directly translate to human corneal infections. The abstract does not report specific sample sizes per group, quantitative ROS/NET reduction values, or visual outcome measures. The P. aeruginosa model represents one type of bacterial keratitis; efficacy against other pathogens is unknown.
How to read the evidence
This is a preliminary animal study using a mouse corneal infection model. While both in vivo and in vitro results are consistent, no human trials have been conducted for this specific application of Tβ4.
When this study was published
Published in 2021, this study builds on a body of earlier work by the same group on Tβ4 in ocular infectious disease. The findings remain relevant as Tβ4 continues to be investigated for various wound healing and anti-inflammatory applications.
The bigger picture
Thymosin beta-4 has been studied across wound healing, cardiac repair, and neurological injury. This study adds ocular infection to the list and reveals a nuanced mechanism: Tβ4 doesn't just reduce inflammation broadly but specifically modulates how neutrophils behave — their ROS production, NET formation, and survival. This positions Tβ4 as an immunomodulator rather than an immunosuppressant, which is an important distinction for treating infections where you still need the immune system to work.
Questions still open
- Could Tβ4 combined with antibiotics improve outcomes in human bacterial keratitis, where immune-mediated corneal scarring is a major cause of vision loss?
- Does Tβ4's neutrophil-regulating effect extend to other types of infections beyond P. aeruginosa in the cornea?
- What is the optimal timing and dosing of Tβ4 relative to antibiotic treatment for maximum benefit?
Common questions
What is thymosin beta-4 and what does it normally do in the body?
Why would you add a peptide to antibiotic treatment for an eye infection?
Read the original research
Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function during Pseudomonas aeruginosa-Induced Corneal Infection.
Cells, 10(12)
Citation
Wang, Yuxin; Carion, Thomas W; Ebrahim, Abdul Shukkur; Sosne, Gabriel; Berger, Elizabeth A. (2021). Adjunctive Thymosin Beta-4 Treatment Influences PMN Effector Cell Function during Pseudomonas aeruginosa-Induced Corneal Infection.. Cells, 10(12). https://doi.org/10.3390/cells10123579